Kaitlyn D’Onofrio

DocwireNews

<a href="https://proddocwire.wpengine.com/docwire-pick/prevent-delay-rheumatoid-arthritis/">Rheumatoid arthritis</a> (RA) patients who begin <a href="https://proddocwire.wpengine.com/abstracts/rheumatology-abstracts/rheumatoid-arthritis-abatacept-rituximab/">abatacept</a> treatment before trying another biologic treatment may have higher two-year retention rates compared to patients who are not <a href="https://proddocwire.wpengine.com/abstracts/on-drug-and-drug-free-remission-by-baseline-symptom-duration-abatacept-with-methotrexate-in-patients-with-early-rheumatoid-arthritis/">biologic</a>-na&iuml;ve, according to a recent study.&ldquo;The determination of predictors of treatment retention and differential response will assist the development of the most appropriate, individualized treatment and has the potential to reduce unnecessary adjustments in therapy,&rdquo; the study authors wrote.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/TCTM19?src=hash&amp;ref_src=twsrc%5Etfw">#TCTM19</a> Watkins: abatacept significantly reduced aGVHD and improved DFS on recipients of 7/8 matched grafts c/w historical CIBMTR control <a href="https://t.co/654bS1wMJZ">pic.twitter.com/654bS1wMJZ</a>
&mdash; Aaron Logan, MD, PhD, MPhil (@hemedoc) <a href="https://twitter.com/hemedoc/status/1099458482351284224?ref_src=twsrc%5Etfw">February 23, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>Abatacept Retention Rates Measured in the AbataCepT In rOutiNe clinical practice (ACTION) Study</h2>Results from the AbataCepT In rOutiNe clinical practice (ACTION) study were published in Clinical Rheumatology.ACTION, an international, observational study, included 2,350 <a href="https://proddocwire.wpengine.com/docwire-pick/smoking-incident-rheumatoid-arthritis/">moderate-to-severe RA</a> patients, of whom 673 (28.6%) were biologic na&iuml;ve; the rest (n = 1,677, 71.4%) had prior biologic failure&mdash;most experiencing two or more failures (n = 949, 56.6%), while 728 (43.4%) had one previous biologic failure.Overall two-year abatacept retention rate (95% confidence interval [CI]) was 47.9%. Patients who had never taken a biologic before were more likely to continue taking abatacept than patients with at least one previous biologic failure (54.5% vs. 45.2%) (log-rank P &lt; 0.001). Among previous biologic failure patients, retention was greater in the one failure cohort compared to the two or more failures cohort (50.2% vs. 41.3%) (log-rank P &lt; 0.001). The top two reasons for discontinuation were the same in the biologic-na&iuml;ve and previous failure groups: lack of efficacy (61.4% vs. 67.7%, respectively) and safety (21.3% vs. 21.2%, respectively).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Abatacept is safe and effective in preventing aGVHD &ndash; data in 7/8 is vs CIBMTR control while 8/8 is placebo controlled &ndash; impressive data that should lead to approval. Congrats to <a href="https://twitter.com/kean_leslie?ref_src=twsrc%5Etfw">@kean_leslie</a> &amp; study team <a href="https://twitter.com/hashtag/TCTM19?src=hash&amp;ref_src=twsrc%5Etfw">#TCTM19</a> 1/2 <a href="https://t.co/PRWHfo7sNj">pic.twitter.com/PRWHfo7sNj</a>
&mdash; Miguel Perales M.D. (@DrMiguelPerales) <a href="https://twitter.com/DrMiguelPerales/status/1099460668640632832?ref_src=twsrc%5Etfw">February 24, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Researchers also evaluated retention predictors in 1,603 patients. New biologic patients were less likely to discontinue abatacept if they had a rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) double positive versus double negative at baseline (hazard ratio [HR]: 0.71; 95% CI: 0.53, 0.96; P&thinsp;=&thinsp;0.019), as were those with <a href="https://proddocwire.wpengine.com/docwire-pick/suboptimal-diabetes-screening/">diabetes</a> mellitus (HR, 0.61; 95% CI 0.38, 0.99; P&thinsp;=&thinsp;0.043). Patients living in Germany had greater discontinuation odds compared to those living in Canada, Greece, and Italy (P &lt; 0.001).Patients with previous biologic failure were also less likely to discontinue <a href="https://proddocwire.wpengine.com/docwire-pick/rheumatoid-arthritis-patients-flareups/">abatacept</a> if they were RF and anti-CCP double positive at baseline (HR, 0.76; 95% CI 0.62, 0.94; P&thinsp;=&thinsp;0.035). Primary efficacy failure was associated with an increased risk for abatacept cessation (HR, 1.28; 95% CI 1.00, 1.63; P&thinsp;=&thinsp;0.014). Higher baseline Patient Global Assessment of disease activity score (&ge;&thinsp;70 vs. &lt;&thinsp;70 mm) on a visual analog scale of 0&ndash;100 mm was also associated with greater odds of stopping abatacept at two years (HR, 1.26; 95% CI 1.05, 1.52; P&thinsp;=&thinsp;0.040).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A look at using <a href="https://twitter.com/hashtag/Orencia?src=hash&amp;ref_src=twsrc%5Etfw">#Orencia</a> for patients with <a href="https://twitter.com/hashtag/rheumatoid?src=hash&amp;ref_src=twsrc%5Etfw">#rheumatoid</a> <a href="https://twitter.com/hashtag/arthritis?src=hash&amp;ref_src=twsrc%5Etfw">#arthritis</a>. Based on research from Clinical <a href="https://twitter.com/hashtag/Rheumatology?src=hash&amp;ref_src=twsrc%5Etfw">#Rheumatology</a>. <a href="https://t.co/CyQYKxPBl8">https://t.co/CyQYKxPBl8</a>
&mdash; MedPage Today (@medpagetoday) <a href="https://twitter.com/medpagetoday/status/1100395205826625536?ref_src=twsrc%5Etfw">February 26, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The study authors wrote, in sum, &ldquo;In conclusion, abatacept retention and EULAR response rates were higher in patients who received abatacept as an earlier line of treatment and in those who were seropositive for both RF and anti-CCP; additional predictors of abatacept retention were observed by treatment line. These findings have the potential to inform the development of an individualized treatment plan for the optimal management of patients with moderate-to-severe RA.&rdquo;https://twitter.com/arthritis_bio/status/1097761725598683136

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Abatacept Retention More Likely for New Biologic Patients

Rheumatology

Rheumatoid arthritis (RA) patients who begin abatacept treatment before trying another biologic treatment may have higher two-year retention rates compared to patients who are ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe